Tremelimumab (Imjudo®) in combination with durvalumab (Imfinzi®). HTA ID: 23073

Assessment Status Awaiting full HTA submission from Applicant
HTA ID 23073
Drug Tremelimumab
Brand Imjudo®
Indication Tremelimumab (Imjudo®) in combination with durvalumab (Imfinzi®) is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma.
Assessment Process
Rapid review commissioned 06/12/2023
Rapid review completed 11/01/2024
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tremelimumab in combination with durvalumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 01/02/2024
Pre-submission consultation with Applicant 26/03/2024